Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Schott Pharma AG KGaAMIL:1SXP 65 Forward PE Ratio is 19.64 as of Aug. 06, 2026. GuruFocus rates MIL:1SXP with a GF Score™ of 65/100 and a GF Value™ of €28.30 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 391 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 53.2% on this metric.
Schott Pharma AG KGaA (MIL:1SXP) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Schott Pharma AG KGaA Forward PE Ratio Related Terms
Schott Pharma AG KGaA Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Forward PE Ratio Chart
Schott Pharma AG KGaA Annual Data
Trend
2025-09
Forward PE Ratio
22.47
Schott Pharma AG KGaA Quarterly Data
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
24.15
22.47
14.43
14.46
MIL:1SXP vs ISRG, BDX, MDLN: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Forward PE Ratio falls into.
Schott Pharma AG KGaA Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Schott Pharma AG KGaA (MIL:1SXP) has a Forward PE Ratio of 19.64 as of Aug. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Schott Pharma AG KGaA and its competitors. According to the industry distribution chart, Schott Pharma AG KGaA ranks #208 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is Schott Pharma AG KGaA's Forward PE Ratio too high?
Schott Pharma AG KGaA's current Forward PE Ratio is 19.64. The Medical Devices & Instruments industry median Forward PE Ratio is 19.79. Schott Pharma AG KGaA's value of 19.64 is 0.8% below this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #208 out of 391 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #208 out of 391 companies for Forward PE Ratio. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median Forward PE Ratio is 19.79. Schott Pharma AG KGaA's value of 19.64 is 0.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.79, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Forward PE Ratio of 19.64 is 0.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Forward PE Ratio is 19.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Modestly Undervalued. The stock's GF Value™ is €28.30, compared to a current price of €21.00 — trading 25.8% below its estimated fair value. The current Forward PE Ratio is 19.64 and 0.8% below the Medical Devices & Instruments industry median of 19.79. Schott Pharma AG KGaA's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current Forward PE Ratio is 19.64 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €21.00 is trading 25.8% below its estimated GF Value™ of €28.30.
GuruFocus considers Schott Pharma AG KGaA to be Modestly Undervalued.
Key valuation signals for MIL:1SXP:
Forward PE Ratio: 19.64
GF Value™: €28.30 vs. price of €21.00 (25.8% below fair value)
Industry Position: 0.8% below the Medical Devices & Instruments median (#208 of 391)
No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
65GF Score
Get the complete analysis for MIL:1SXP
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1SXP has been successfully added to your 
